A randomized phase II trial confirmed the efficacy and acceptable tolerability of chemotherapy combined with the poly(ADP-ribose) polymerase inhibitor olaparib for the treatment of platinum-sensitive, recurrent, high-grade serous ovarian cancer. Median progression-free survival in 81 patients treated with olaparib, paclitaxel and carboplatin, followed by olaparib alone, was 12.2 months, compared with 9.6 months in 81 patients receiving initial chemotherapy, then no treatment. The survival benefit of olaparib treatment was greatest for patients with BRCA1 or BRCA2 mutations.
References
Oza, A. M. et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 10.1016/S1470-2045(14)71135-0
Rights and permissions
About this article
Cite this article
Olaparib is efficacious in patients with ovarian cancer. Nat Rev Clin Oncol 12, 64 (2015). https://doi.org/10.1038/nrclinonc.2014.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.229